Jean-Pierre Lindenmayer1, Anzalee Khan2, Herbert Lachman3, Susan R McGurk4, Abraham Goldring5, Amod Thanju5, Saurabh Kaushik6. 1. Manhattan Psychiatric Center, New York, NY, United States; New York University Medical Center, New York, NY, United States; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, United States. Electronic address: Lindenmayer@nki.rfmh.org. 2. Manhattan Psychiatric Center, New York, NY, United States; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, United States; ProPhase LLC, New York, NY, United States. 3. Albert Einstein College of Medicine, Bronx, NY, United States. 4. Boston University, Boston, MA, United States. 5. Manhattan Psychiatric Center, New York, NY, United States; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, United States. 6. New York Medical College, Valhalla, NY, United States.
Abstract
BACKGROUND: A functional polymorphism of the catechol-O-methyltransferase (COMT) gene (Val158Met) partially appears to influence cognitive performance in schizophrenia subjects and healthy controls by modulating prefrontal dopaminergic activity. This study evaluated the association of the COMT Val108/158 Met genotype with response to computerized neurocognitive remediation (CRT). METHOD: 145 subjects with DSM-IV-TR schizophrenia or schizoaffective disorder were genotyped via saliva sampling. Subjects were evaluated on neurocognitive assessments (MATRICS) and clinical symptoms (PANSS) at baseline and endpoint after 12weeks of CRT. "Improvement" was defined as ≥67% of cognitive domains (≥4) showing performance increases. If ≤67% (≤2) of domains improved, the change was defined as "minimal improvement." A general linear model was conducted for change of each cognitive domain. RESULTS: Of 145 subjects, data from 138 subjects were usable. Distribution of COMT genotype: Met/Met: 28 (20.29%), Val/Met: 61 (44.20%), and Val/Val: 49 (35.51%). No significant differences were seen among genotype groups at baseline or across genotype group for "Improvement" vs. "Minimal Improvement." GLM analysis showed significant differences in Verbal Learning (p=0.003), Visual Learning (p=0.014) and Attention/Vigilance (p=0.011) favoring Met/Met and Val/Met groups. CONCLUSIONS: The low activity Met allele (Met/Met; Val/Met) was associated with significantly greater improvements in the MATRICS domains of Verbal Learning, Visual Learning and Attention/Vigilance after CRT.
BACKGROUND: A functional polymorphism of the catechol-O-methyltransferase (COMT) gene (Val158Met) partially appears to influence cognitive performance in schizophrenia subjects and healthy controls by modulating prefrontal dopaminergic activity. This study evaluated the association of the COMT Val108/158 Met genotype with response to computerized neurocognitive remediation (CRT). METHOD: 145 subjects with DSM-IV-TR schizophrenia or schizoaffective disorder were genotyped via saliva sampling. Subjects were evaluated on neurocognitive assessments (MATRICS) and clinical symptoms (PANSS) at baseline and endpoint after 12weeks of CRT. "Improvement" was defined as ≥67% of cognitive domains (≥4) showing performance increases. If ≤67% (≤2) of domains improved, the change was defined as "minimal improvement." A general linear model was conducted for change of each cognitive domain. RESULTS: Of 145 subjects, data from 138 subjects were usable. Distribution of COMT genotype: Met/Met: 28 (20.29%), Val/Met: 61 (44.20%), and Val/Val: 49 (35.51%). No significant differences were seen among genotype groups at baseline or across genotype group for "Improvement" vs. "Minimal Improvement." GLM analysis showed significant differences in Verbal Learning (p=0.003), Visual Learning (p=0.014) and Attention/Vigilance (p=0.011) favoring Met/Met and Val/Met groups. CONCLUSIONS: The low activity Met allele (Met/Met; Val/Met) was associated with significantly greater improvements in the MATRICS domains of Verbal Learning, Visual Learning and Attention/Vigilance after CRT.
Authors: D R Weinberger; M F Egan; A Bertolino; J H Callicott; V S Mattay; B K Lipska; K F Berman; T E Goldberg Journal: Biol Psychiatry Date: 2001-12-01 Impact factor: 13.382
Authors: A Meyer-Lindenberg; T Nichols; J H Callicott; J Ding; B Kolachana; J Buckholtz; V S Mattay; M Egan; D R Weinberger Journal: Mol Psychiatry Date: 2006-06-20 Impact factor: 15.992
Authors: M F Egan; T E Goldberg; B S Kolachana; J H Callicott; C M Mazzanti; R E Straub; D Goldman; D R Weinberger Journal: Proc Natl Acad Sci U S A Date: 2001-05-29 Impact factor: 11.205
Authors: Ikwunga Wonodi; O Colin Stine; Braxton D Mitchell; Robert W Buchanan; Gunvant K Thaker Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2003-07-01 Impact factor: 3.568
Authors: Francesc Estrada; Josep Maria Crosas; Maribel Ahuir; Sara Pérez-Muñoz; Wanda Zabala; Raquel Aguayo; Juan David Barbero; Itziar Montalvo; Meritxell Tost; Laura Llauradó; Armand Guardia; Diego Palao; José Antonio Monreal; Javier Labad Journal: Front Psychiatry Date: 2020-07-07 Impact factor: 4.157
Authors: Stefano Barlati; Giacomo Deste; Alessandro Galluzzo; Anna Paola Perin; Paolo Valsecchi; Cesare Turrina; Antonio Vita Journal: Front Pharmacol Date: 2019-01-10 Impact factor: 5.810